We’re tracking the latest on the coronavirus outbreak and the global response.

Sign up here for our daily newsletter on what you need to know.

AstraZeneca Plc said a careful review of all available data of the more than 17 million people in the European Union and the U.K. it has vaccinated against so far against Covid-19 shows no evidence of an increased risk of pulmonary embolism, deep vein thrombosis (DVT) or thrombocytopenia.

The company says it is continually monitoring the safety of its vaccine.

To view the source of this information click


    Before it’s here, it’s on the Bloomberg Terminal.